Glucagon-like peptide-1 receptor agonists and mental health: A meta-analysis of randomized controlled trials

Affiliations

¹ Experimental and Clinical Biomedical Sciences Department, Diabetology Unit, Florence University, Florence, Italy.
² Health Sciences Department, Psychiatry Unit, Florence University, Florence, Italy.

Meta-Analysis

Giovanni Antonio Silverii et al. Diabetes Obes Metab. 2024 Jun.

. 2024 Jun;26(6):2505-2508.

doi: 10.1111/dom.15538. Epub 2024 Mar 6.

¹ Experimental and Clinical Biomedical Sciences Department, Diabetology Unit, Florence University, Florence, Italy.
² Health Sciences Department, Psychiatry Unit, Florence University, Florence, Italy.

No abstract available

References

1. Lau D, Gamble J. Suicidality among users of glucagon‐like peptide‐1 receptor agonists: an emerging signal? Diabetes Obes Metab. 2024;dom.15459. doi:10.1111/dom.15459
1. Knudsen LB, Secher A, Hecksher‐Sørensen J, Pyke C. Long‐acting glucagon‐like peptide‐1 receptor agonists have direct access to and effects on pro‐opiomelanocortin/cocaine‐ and amphetamine‐stimulated transcript neurons in the mouse hypothalamus. J Diabetes Investig. 2016;7:56‐63. doi:10.1111/jdi.12463
1. Cukierman‐Yaffe T, Gerstein HC, Colhoun HM, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020;19:582‐590. doi:10.1016/S1474‐4422(20)30173‐3
1. Detka J, Głombik K. Insights into a possible role of glucagon‐like peptide‐1 receptor agonists in the treatment of depression. Pharmacol Rep. 2021;73:1020‐1032. doi:10.1007/s43440‐021‐00274‐8
1. Heneghan HM, Heinberg L, Windover A, Rogula T, Schauer PR. Weighing the evidence for an association between obesity and suicide risk. Surg Obes Relat Dis. 2012;8:98‐107. doi:10.1016/j.soard.2011.10.007